SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharma gets RBI’s nod to raise FII limit to 49%

20 May 2015 Evaluate

Reserve Bank of India (RBI) has allowed foreign institutional investors (FIIs) to buy up to 49% stake in Glenmark Pharmaceuticals. FIIs through primary market and stock exchanges, can now purchase up to 49% of the paid up capital of the company under the Portfolio Investment Scheme (PIS).

In December, the company had received shareholder nod for enhancing the limit from 40% to 49% for the purchase of its equity shares and convertible debentures by FIIs. As on March 2015, FIIs hold 34.71% stake in the pharma major.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical company and ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues as per SCRIP 100 Rankings.

Glenmark Pharma Share Price

2364.35 -6.70 (-0.28%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×